FDA approval of supplemental NDA for Firdapse expanding patient population to include pediatric patients with Lambert-Eaton myasthenic syndrome
Catalyst Pharmaceuticals, Inc. a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, announced that the FDA has approved the supplemental New Drug Application) to expand the indicated age range for Firdapse (amifampridine) Tablets 10 mg to include pediatric patients, six years of age and older for the treatment of Lambert-Eaton myasthenic syndrome
Firdapse is currently approved in the U.S. and Canada for the treatment of LEMS in adult patients.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins